51
|
Jain M, Meilleur K, Norato G, Waite M, Leach M, Donkervoort S, Foley A, Bönnemann C. CONGENITAL MUSCULAR DYSTROPHIES. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
52
|
Camelo C, Da Silva A, Reed U, Bönnemann C, Zanoteli E. CONGENITAL MYOPATHIES: GENERAL AND RYR1. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
53
|
Donkervoort S, Müller J, Knierim E, Bharucha-Goebel D, Dyack S, Burns D, Hu Y, Baker L, Ezzo D, Scavina M, Foley A, Schülke M, Schülke M, Bönnemann C. Recessive mutation in EXOSC9 disrupts the exosome complex resulting in a novel form of cerebellar hypoplasia/atrophy with early motor neuronopathy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
54
|
Oates E, Yau K, Jones K, Smith J, Cummings B, Farrar M, Cooper S, Lek M, Hoffman E, Straub V, Ferreiro A, Udd B, Beggs A, Bönnemann C, North K, MacArthur D, Granzier H, Muntoni F, Davis M, Laing N. Do titin developmental isoforms contribute to the pathogenesis of congenital titinopathy? Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.513] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
55
|
Schartner V, Romero N, Donkervoort S, Treves S, Munot P, Pierson T, Dabaj I, Malfatti E, Zaharieva I, Zorzato F, Eymard B, Taratuto A, Boland A, Deleuze J, Biancalana V, Quijano-Roy S, Muntoni F, Bönnemann C, Laporte J. Dihydropyridine receptor (DHPR, CACNA1S) congenital myopathy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
56
|
Moreno CDAM, Abath Neto O, Donkervoort S, Hu Y, Reed UC, Oliveira ASB, Bönnemann C, Zanoteli E. Clinical and Histologic Findings in ACTA1-Related Nemaline Myopathy: Case Series and Review of the Literature. Pediatr Neurol 2017; 75:11-16. [PMID: 28780987 DOI: 10.1016/j.pediatrneurol.2017.04.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Revised: 03/27/2017] [Accepted: 04/02/2017] [Indexed: 10/19/2022]
Abstract
BACKGROUND Nemaline myopathy is a rare congenital disease of skeletal muscle characterized by muscle weakness and hypotonia, as well as the diagnostic presence of nemaline rods in skeletal muscle fibers. Nemaline myopathy is genetically and phenotypically heterogeneous and, so far, mutations in 11 different genes have been associated with this disease. Dominant mutations in ACTA1 are the second most frequent genetic cause of nemaline myopathy and can lead to a variety of clinical and histologic phenotypes. PATIENTS AND METHODS We present a series of ACTA1-related cases from a Brazilian cohort of 23 patients with nemaline myopathy, diagnosed after Sanger sequencing the entire coding region of ACTA1, and review the literature on ACTA1-related nemaline myopathy. RESULTS The study confirmed ACTA1 mutations in four patients, including one with intranuclear rods, one with large intracytoplasmic aggregates, and two with nemaline intracytoplasmic rods. A repeat muscle biopsy in one patient did not show histological progression. CONCLUSION Despite the recognized phenotypic variability in ACTA1-related nemaline myopathy, clinical and histological presentations appear to correlate with the position of the mutation, which confirms emerging genotype/phenotype correlations and better predict the prognosis of affected patients.
Collapse
|
57
|
Ben Yaou R, Dabaj I, Yun P, Norato G, Xiong H, Nascimento A, Maggi L, Sarkozy A, Monges S, Bertoli M, Komaki H, Mercuri E, Zanoteli E, Bushby K, Muntoni F, Rutkowski A, Bönnemann C, Quijano-Roy S, Bonne G. First results from the international LMNA -related congenital and childhood onset muscular dystrophy retrospective natural history study. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
58
|
Reghan Foley A, Donkervoort S, Bolduc V, Hu Y, Cummings B, Lek M, Sarkozy A, Jimenez-Mallebrera C, Butterfield R, Lamande S, Kirschner J, Allamand V, Stojkovic T, Quijano-Roy S, Gualandi F, Ferlini A, Bertini E, MacArthur D, Muntoni F, Bönnemann C. A common COL6A1 deep-intronic pseudo-exon inserting mutation causes a distinct phenotype of Ullrich congenital muscular dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
59
|
Leach M, Foley A, Averion G, Hu Y, Yun P, DeCoster J, Arevalo C, Mendoza C, Mayer O, Hausmann R, Cheung K, Bönnemann C. Congenital muscular dystrophy ascending multiple dose cohort study analyzing pharmacokinetics at three dose levels in children and adolescents with assessment of safety and tolerability of omigapil (CALLISTO) trial update. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
60
|
Dabaj I, Ben Yaou R, Bönnemann C, Nascimento A, Rutkowski A, Erazo Torricelli R, Muntoni F, Lagrue E, Dowling J, Bushby K, Casteglioni C, Kleinsteuber K, Lorenzo M, Ishiyama A, Sejersen T, Gurgel-Giannetti J, Monges S, Bonne G, Quijano-roy S. Corticosteroid treatment in early-onset lamin A/C related muscular dystrophies. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
61
|
Korinthenberg R, Schorling D, Rost S, Krueger M, Beytia M, Mueller C, Bönnemann C, Kirschner J. Severe congenital myopathy with myasthenic features and lethal neurodegeneration – A new ALG14-related phenotype? Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
62
|
Jungbluth H, Dowling JJ, Ferreiro A, Muntoni F, Bönnemann C, Dirksen R, Faure J, Hamilton S, Hopkins P, Marks A, Marty I, Meilleur K, Riazi S, Sewry C, Treves S, Voermans N, Zorzato F. 217th ENMC International Workshop: RYR1-related myopathies, Naarden, The Netherlands, 29–31 January 2016. Neuromuscul Disord 2016; 26:624-33. [DOI: 10.1016/j.nmd.2016.06.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2016] [Accepted: 06/02/2016] [Indexed: 12/22/2022]
|
63
|
Gao QQ, Wyatt E, Goldstein JA, LoPresti P, Castillo LM, Gazda A, Petrossian N, Earley JU, Hadhazy M, Barefield DY, Demonbreun AR, Bönnemann C, Wolf M, McNally EM. Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. J Clin Invest 2015; 125:4186-95. [PMID: 26457733 DOI: 10.1172/jci82768] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 09/03/2015] [Indexed: 01/16/2023] Open
Abstract
Exon skipping uses antisense oligonucleotides as a treatment for genetic diseases. The antisense oligonucleotides used for exon skipping are designed to bypass premature stop codons in the target RNA and restore reading frame disruption. Exon skipping is currently being tested in humans with dystrophin gene mutations who have Duchenne muscular dystrophy. For Duchenne muscular dystrophy, the rationale for exon skipping derived from observations in patients with naturally occurring dystrophin gene mutations that generated internally deleted but partially functional dystrophin proteins. We have now expanded the potential for exon skipping by testing whether an internal, in-frame truncation of a transmembrane protein γ-sarcoglycan is functional. We generated an internally truncated γ-sarcoglycan protein that we have termed Mini-Gamma by deleting a large portion of the extracellular domain. Mini-Gamma provided functional and pathological benefits to correct the loss of γ-sarcoglycan in a Drosophila model, in heterologous cell expression studies, and in transgenic mice lacking γ-sarcoglycan. We generated a cellular model of human muscle disease and showed that multiple exon skipping could be induced in RNA that encodes a mutant human γ-sarcoglycan. Since Mini-Gamma represents removal of 4 of the 7 coding exons in γ-sarcoglycan, this approach provides a viable strategy to treat the majority of patients with γ-sarcoglycan gene mutations.
Collapse
MESH Headings
- Animals
- Codon, Nonsense/genetics
- Diaphragm/metabolism
- Diaphragm/pathology
- Drosophila Proteins/deficiency
- Drosophila Proteins/genetics
- Drosophila melanogaster/genetics
- Dystrophin-Associated Protein Complex/chemistry
- Exons
- Fibrosis
- Genetic Therapy
- HEK293 Cells
- Humans
- Mice
- Mice, Transgenic
- Muscle, Skeletal/metabolism
- Muscle, Skeletal/pathology
- Muscular Dystrophies, Limb-Girdle/genetics
- Muscular Dystrophies, Limb-Girdle/therapy
- Muscular Dystrophy, Animal/genetics
- Muscular Dystrophy, Animal/pathology
- Muscular Dystrophy, Animal/therapy
- Mutation
- Myocardium/metabolism
- Myocardium/pathology
- Oligonucleotides, Antisense/pharmacology
- Oligonucleotides, Antisense/therapeutic use
- Protein Engineering
- Protein Interaction Mapping
- Protein Structure, Tertiary
- RNA, Messenger/chemistry
- RNA, Messenger/genetics
- Recombinant Fusion Proteins/metabolism
- Sarcoglycans/biosynthesis
- Sarcoglycans/chemistry
- Sarcoglycans/deficiency
- Sarcoglycans/genetics
- Sarcolemma/metabolism
- Sequence Deletion
Collapse
|
64
|
Mohassel P, Donkervoort S, Dastgir J, Munell F, Sanchez A, Haverlova J, Manzur A, Quijano-Roy S, Tasca G, Udd B, Muntoni F, Bönnemann C. Muscle MRI findings in myopathies due to FHL1 mutation. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
65
|
Rooney J, Zou Y, Cowling B, Mitchell C, Bönnemann C. Late-onset mild myopathy with protein aggregates in two transgenic mouse models of FHL1. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
66
|
Donkervoort S, Chan S, Bradley N, Foley A, Nguyen D, Hu Y, Leach M, Thangarajh M, Reyes C, Nance J, Moore S, Bönnemann C. Cytoplasmic body pathology in severe ACTA1-myopathy in the absence of typical nemaline-rod histology. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
67
|
Willcocks R, Triplett W, Lott D, Forbes S, Dastgir J, Bönnemann C, Vandenborne K, Walter G. Quantitative MRI and MRS detect alterations in muscle quality in both congenital muscular dystrophy and Duchenne muscular dystrophy. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
68
|
Donkervoort S, Yang M, Leach M, Medne L, Yum S, Hotchkiss L, Rutkowski A, Chatfield K, Auerbach S, Miyamoto S, Bönnemann C. Cardiomyopathy in patients with ACTA1-myopathy. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
69
|
Papadaki M, Marston S, Memo M, Messer A, Donkervoort S, Bönnemann C, Nowak K, Ong R, McNamara E. Molecular basis of stiff patient syndrome caused by mutations in ACTA1 and TPM3. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
70
|
Nichols C, Lehky T, Waite M, Duong T, Nelson L, Keller K, Lott D, Meilleur K, Collins J, Dastgir J, Vuillerot C, Rutkowski A, Donkervoort S, Leach M, Jain M, Bönnemann C. Electrical impedance myography as a potential biomarker in individuals with COL6-related dystrophy. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
71
|
Bharucha-Goebel D, Ezzo D, Jain M, Waite M, Nichols C, Lehky T, Mohassel P, Donkervoort S, Leach M, Dastgir J, Marra J, Zein W, Bönnemann C. Giant axonal neuropathy – clinical trial preparedness and evaluation of markers of disease severity. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
72
|
Mohassel P, Rooney J, Zou Y, Bönnemann C. Col6A2 null mice are a new mouse model of collagen-VI related dystrophies and relevant to the human disease. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
73
|
R'guiba N, Annoussamy M, Cardas R, Lilien C, Ollivier G, Muntoni F, Bönnemann C, Biancalana V, Cuisset J, Mayer M, Landy H, Ramsdell D, Nelken M, Le Moing A, Gidaro T, Mingozzi F, Buj-Bello A, Hogrel J, Voit T, Servais L. Natural history and functional status of patients with myotubular myopathy enrolled in a prospective and longitudinal study. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
74
|
Guadagnin E, Dastgir J, Yang L, Johnson K, Wang Q, Hu Y, Dillmann A, Cookson M, Bönnemann C. G.P.213. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
75
|
Hu Y, Donkervoot S, Stojkovic T, Voermans N, Foley A, Leach M, Dastgir J, Bolduc V, Cullup T, Becdelièvre A, Yang L, Su H, Meilleur K, Schindler A, Kamsteeg E, Richard P, Butterfield R, Winder T, Crawford T, Weiss R, Muntoni F, Allamand V, Bönnemann C. G.P.214. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|